NCT04999761 2024-09-25AB122 Platform StudyTaiho Pharmaceutical Co., Ltd.Phase 1 Recruiting917 enrolled
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled